ong Term Administration Study of OPC-12759 Ophthalmic Suspension in dry eye patients

Otsuka Pharmaceuticals Co., Ltd.0 个研究点目标入组 153 人开始时间: 2009年1月8日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Out patient;
•2.Ocular discomfort severity is moderate to severe;
•3.Cornaeal-conjunctival damage is moderate to severe;
•4.Unanaesthetized Schirmer's test score of 5mm/5 minutes or less, or tear breakup time is 5 seconds or less;
•5.Best corrected visual acuity of 0.2 or better in both eyes.

•1.Presence of anterior segment disease or disorder other than that associated with keratoconjunctivitis scicca;
•2.Ocular hypertension patient or glaucoma patient with ophthalmic solution;
•3.Anticipated use of any topically-instilled ocular medications or patients who cannot discontinue the use during the study;
•4.Anticipated use of contact lens during the study;
•5.Patient with punctal plug;
•6.Any history of ocular surgery within 12 months;
•7.Female patients who are pregnant, possibly pregnant or breast feeding;
•8.Known hypersensitivity to any component of the study drug or procedual medications;
•9.Receipt of any investigational product within 4 months.

发起方

Otsuka Pharmaceuticals Co., Ltd.